NASDAQ:PRTO - Proteon Therapeutics Stock Price, Forecast & News

Proteon Therapeutics trades on the NASDAQ under the ticker symbol "PRTO."

Proteon Therapeutics Inc (NASDAQ:PRTO) issued its earnings results on Thursday, October, 31st. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.09) by $0.01. View Proteon Therapeutics' Earnings History.

Proteon Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Proteon Therapeutics.

5 brokerages have issued twelve-month target prices for Proteon Therapeutics' shares. Their forecasts range from $1.00 to $5.00. On average, they anticipate Proteon Therapeutics' share price to reach $3.33 in the next twelve months. This suggests that the stock has a possible downside of 89.6%. View Analyst Price Targets for Proteon Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Proteon Therapeutics in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Proteon Therapeutics.

News stories about PRTO stock have trended very positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Proteon Therapeutics earned a news impact score of 3.1 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Proteon Therapeutics.

Proteon Therapeutics saw a drop in short interest in the month of January. As of January 15th, there was short interest totalling 58,500 shares, a drop of 52.6% from the December 31st total of 123,400 shares. Based on an average daily volume of 7,400 shares, the short-interest ratio is presently 7.9 days. Approximately 20.1% of the company's shares are short sold. View Proteon Therapeutics' Current Options Chain.

Some companies that are related to Proteon Therapeutics include Audentes Therapeutics (BOLD), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Alector (ALEC), Regenxbio (RGNX), Bill.com (RVMD), Cortexyme (CRTX), Coherus Biosciences (CHRS), SpringWorks Therapeutics (SWTX), Beam Therapeutics (BEAM), I-Mab (BDTX), Editas Medicine (EDIT), NanoString Technologies (NSTG), Orchard Therapeutics (ORTX) and BAVARIAN NORDIC/S (BVNRY).

Based on aggregate information from My MarketBeat watchlists, some companies that other Proteon Therapeutics investors own include Celgene (CELG), SCYNEXIS (SCYX), Synergy Pharmaceuticals (SGYP), Sierra Oncology (SRRA), Verastem (VSTM), vTv Therapeutics (VTVT), Agile Therapeutics (AGRX), Biocept (BIOC), Fate Therapeutics (FATE) and Idera Pharmaceuticals (IDRA).

Proteon Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Abingworth LLP (9.67%), Renaissance Technologies LLC (3.81%), Perceptive Advisors LLC (1.54%), Fairmount Funds Management LLC (1.54%), Perceptive Advisors LLC (1.54%) and Ikarian Capital LLC (1.52%). View Institutional Ownership Trends for Proteon Therapeutics.

PRTO stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG. View Insider Buying and Selling for Proteon Therapeutics.

PRTO stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Perceptive Advisors LLC, Fairmount Funds Management LLC, Ikarian Capital LLC, Abingworth LLP, Renaissance Technologies LLC and Wedbush Securities Inc.. View Insider Buying and Selling for Proteon Therapeutics.

Shares of PRTO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PRTO stock can currently be purchased for approximately $32.12.

Proteon Therapeutics has a market capitalization of $712.39 million. The biopharmaceutical company earns $-20,730,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis. Proteon Therapeutics employs 17 workers across the globe.View Additional Information About Proteon Therapeutics.

The official website for Proteon Therapeutics is http://www.proteontherapeutics.com/.

Proteon Therapeutics' mailing address is 200 WEST STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 781-890-0102 or via email at [email protected]